英菲格拉替尼国内上市了吗？

Infigratinib was granted Fast Track designation by the FDA in early January 2020. The drug is an oral FGFR tyrosine kinase inhibitor. For adult patients with previously treated, unresectable locally advanced or metastatic FGFR2 fusion cholangiocarcinoma. Today we will take a closer look at whether Infigratinib is available in China?

Infigratinib is not currently on the market in China. Patients cannot buy this drug in hospital pharmacies. Patients can choose to purchase the drug overseas, but the journey is long and the financial burden is relatively heavy. The editor recommends that patients obtain drugs through Medical Companion Travel. Medical Companion Travel is a professional overseas medical service organization in China that can help patients obtain overseas drugs. Direct mail from pharmaceutical companies is cost-effective and can reduce a considerable financial burden. For specific drug prices and purchase procedures, patients can consult Medical Companion Travel service staff.

Infigratinib induces tumor cell death by reducing cancer cell proliferation. The trial studied the efficacy of infigratinib as a third-line or above treatment for patients with FGFR2 fusion-positive cholangiocarcinoma. 71 patients received infigratinib, 125 mg once a day, orally for 21 days, with a 28-day cycle, until disease progression or unacceptable toxicity. The results showed that the median PFS of patients who received third-line or above treatment with infigratinib was 6.77 months; in the case of second-line treatment, the median PFS of patients was 4.63 months. In other words, compared with the second-line standard chemotherapy regimen, infigratinib in third-line and above-line treatment has greater benefits in both PFS and ORR.

(Incidence ≥20%): abdominal pain, dry mouth, nail toxicity, stomatitis, dry eye, fatigue, alopecia, dysgeusia, constipation, eyelash changes, diarrhea, dry skin, loss of appetite, palmoplantar erythema sensory syndrome, joint pain, blurred vision and vomiting. Patients should not change the dosage and usage at will during treatment with Infigratinib to avoid intolerance reactions.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: